Allogene Therapeutics, Inc. — Form 8-K Summary
Reporting period and context: Filed December 15, 2021, reporting events beginning December 10, 2021. Allogene is developing investigational allogeneic CAR T-cell therapies for hematologic cancers. The filing reports expanded facilities, clinical-trial results presented at the 2021 ASH Annual Meeting, and a clinical hold affecting certain trials.
Material Lease Amendments
- The company amended its headquarters lease to add approximately 47,566 square feet of office and laboratory space in South San Francisco. Existing headquarters space is approximately 68,072 square feet.
- The expansion is expected to commence April 1, 2022, with four months of rent abatement. Rent thereafter is $309,179 per month, or $6.50 per square foot, increasing approximately 3.5% annually.
- The combined headquarters lease expires March 31, 2032, with a potential eight-year extension option. The company will increase its landlord letter of credit to $1,779,784.
- A separate approximately 14,943-square-foot lease was extended to be coterminous with the headquarters lease.
Clinical Results and Key Metrics
| Program | Key results | Safety observations |
|---|---|---|
| ALLO-501 — Phase 1 ALPHA | Among 40 efficacy-evaluable, CAR T-naive patients, ORR was 75% and complete response rate was 53%. In follicular lymphoma, ORR was 81% and CR rate was 58%; in large B-cell lymphoma, ORR was 64% and CR rate was 43%. | No dose-limiting toxicities or GvHD. Grade 3 or higher CRS occurred in 4% and grade 3 or higher neurotoxicity in 4% of all patients. Five treatment-emergent deaths absent disease progression had been previously reported. |
| ALLO-501A — Phase 1 ALPHA2 | Among 25 efficacy-evaluable patients, ORR was 48% and CR rate was 28%. The longest ongoing CR was 15+ months. | No GvHD or treatment-emergent deaths were reported. A chromosomal abnormality in a Consolidation 2 patient is under investigation. |
| ALLO-715 — Phase 1 UNIVERSAL | Of 43 patients evaluable for safety and efficacy, the selected DL3/FCA cohort had a 71% ORR and 46% VGPR-or-better rate. Median efficacy follow-up was 3.8 months; median duration of response was 8.3 months. | No GvHD. CRS occurred in 56% of patients, primarily grades 1–2. Infection occurred in 54%, including three grade 5 infections. Grade 3 or higher neutropenia occurred in 70%; low-grade neurotoxicity occurred in 14%. |
Outlook, Risks, and Unusual Items
- A clinical hold is in place on the ALPHA and ALPHA2 trials while the chromosomal abnormality is investigated and the company discusses resolution with the FDA.
- Subject to resolving the hold, management intends to initiate a Phase 2 pivotal trial of ALLO-501A in relapsed/refractory large B-cell lymphoma in 2022, using the Consolidation 1 regimen.
- The company also targeted 2022 data from additional ALLO-715 consolidation and combination strategies and from the Phase 1 dose-escalation portion of the IGNITE trial evaluating ALLO-605.
- Clinical results are preliminary and may change as follow-up continues. Cross-trial comparisons with autologous CAR T therapies may not be meaningful because of differences in trial design, patient populations, follow-up, and products.
- The filing includes customary forward-looking statement risks, including clinical-hold resolution, regulatory discussions, trial timing, future clinical outcomes, manufacturing and development execution, and the potential benefits of the company’s technology.
Financial Position and Operating Metrics
This Form 8-K does not provide revenue, net income or loss, operating cash flow, cash and investments, margins, debt balances, liquidity runway, or financial guidance. The principal financial commitment disclosed is the expanded lease obligation and the related $1,779,784 letter of credit.
Facts Investors Should Verify
- Whether and when the FDA clinical hold on ALPHA and ALPHA2 was resolved and whether planned Phase 2 activity commenced.
- Follow-up durability, survival, treatment-emergent deaths, and additional safety findings for ALLO-501, ALLO-501A, and ALLO-715.
- The nature and regulatory implications of the chromosomal abnormality identified in ALPHA2 Consolidation 2.
- The company’s subsequent financial statements for lease liabilities, letter-of-credit requirements, cash resources, burn rate, and liquidity runway.
- Whether the reported response rates remain consistent in larger, later-stage, and more mature datasets.